2[2]Modena MG,Aveta P,Menozzi A,et al.Aldoste rone inhibition lia its collagen synthesis and progressive left ventricular enlargement after anterior myocardial infraction[J].Am Heart J,2001,141:41 -45.
3[3]Hayashi M,Tsutam oto T,Wada A,et al.Immediate administration of mineralocoticoid receptor antagonist spironolactone prevents postinfract left ventricular remodeling associated with suppressin of a acute myocardial collagen synthesis in patients with first anterior acute myocardial infraction[J].Circulation,2003,107:2559-2565.
5[5]Struthers AD.Aldosterone escape during angiotensin-converting enzy me inhibitor therapy in chronic hearn failure[J].J Card Fail,1996,2:24-54.
二级参考文献18
1Farquharson C A, Struthers A D. spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunctlon, and suppresses vascu|ar angiotensin Ⅰ /angiotensin Ⅱ conversion in patients with chronic heart failure [J]. Circulation,2000,101(6) : 594-597.
2Francis J, Weiss R M, Wei S G. Central mineralocorticoid teceptor blockade improves volume regulation and reduces sympathetic drive in heart failure[J]. Am J physiol Heart Cire physiol, 2001,281(5) : H2241-2251.
3Yee K M, Pringle S D, Struthers A D, et al. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure[J]. J Am Coll Cardiol, 2001,37(7) : 1800-1807.
4MacFadyen R J, Barr C S, Struthers A D, et al . Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients[J]. Cardiovasc Res,1997,35(1):30-34.
5Korkmaz M E, Muderrisoglu H, Ulucam M, et al . Effects of spironolaction on heart rate variability and left ventricular systolic function in severe ischemic heart failure[J]. Am J Cardiol,2000,86(6) :649-653.
6Ramires F J, Mansur A, Coelho O, et al. Effect of spironolaetone on ventrieular arrhythmias in congestive heart failure, secondary to idiopathic dilated or to ischemic cardiomyopathy[J]. Am J Cardiol,2000,85(10) :1207-1211.
7Cserhalmi L. Effect of combined captopril-spironolactone therapy of cardiac insufficiency o kidney function and serum electrolyte values[J]. Orv Hetil, 1998,139(2) : 63-66.
8The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The randomized aldactone evaluation study [RALES] [J]. Am JCardiol, 1996,78(8) : 902-907.
9Van Vliet A A,Donker A J,Nauta J J, et al . Spironolactone in congestive heart failure refractory to high-dose loop diureti and low-dose angiotensin converting enzyme inhibitor[J]. Am J Cardiol, 1993,71(3) : 21A-28A.
10Hensen J, Abraham W T, Durr J A, et al. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention[J]. Am J Nephrol,1991,11(6):441-446.
9BADLE M, ROIG E,PEREZ VILLA F,et al. Increased expression of the rennin angiotensin system and mast cell density but not of an giotensin convertingenzyme I in late stages of human heart failure [ J ]. J Heart Lung Transplant,2006,25 ( 9 ) : 1117 - 1125.
